达托霉素

2003年，达托霉素被FDA批准在美国上市，主要用于皮肤和软组织感染治疗。

Daptomycin was approved by FDA in 2003 , and it was used in skin and soft tissue infection .

达托霉素能钙依赖性的使细菌细胞膜去极化并导致细胞膜电位的丢失，抑制DNA、RNA和蛋白的合成从而导致细胞死亡。

Daptomycin exhibits Ca-dependent depolarisation of the bacterial membrane resulting in loss of membrane potential leading to inhibition of DNA , RNA and protein synthesis which results in cell death .

但该化合物并不影响用于治疗MRSA感染的其它药物（包括万古霉素、达托霉素或利福平）；

The agent does not affect other drugs used to treat MRSA infections , including vancomycin , daptomycin , or rifampicin ;

因此，对达托霉素发酵进行深入的研究和开发具有重要意义。

Therefore , it is of great importance to enhance the research and development of daptomycin production process .

目前达托霉素生物合成途径及相关功能基因已经被成功解析，应用合成生物学技术可以对其生物合成基因簇进行人为的遗传操作，如通过基因替换筛选新型抗生素、通过更改宿主提高表达量等等。

The biosynthetic pathway of daptomycin and related functional gene has been successfully resolved , the application of synthetic biology techniques can manipulate its biosynthesis gene cluster artificially , such as screening of novel antibiotics by gene replacement , elevation of expression amount by changing the host and so on .